Candriam S.C.A. Has $6.27 Million Stake in Humana Inc. (NYSE:HUM)

Candriam S.C.A. lifted its position in shares of Humana Inc. (NYSE:HUM - Free Report) by 178.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,710 shares of the insurance provider's stock after buying an additional 15,833 shares during the period. Candriam S.C.A.'s holdings in Humana were worth $6,269,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Pinnacle Wealth Management Advisory Group LLC raised its holdings in Humana by 3.6% during the fourth quarter. Pinnacle Wealth Management Advisory Group LLC now owns 1,070 shares of the insurance provider's stock worth $272,000 after acquiring an additional 37 shares in the last quarter. Atlas Brown Inc. raised its holdings in Humana by 0.6% during the fourth quarter. Atlas Brown Inc. now owns 6,352 shares of the insurance provider's stock worth $1,611,000 after acquiring an additional 38 shares in the last quarter. Moors & Cabot Inc. raised its holdings in Humana by 2.5% during the third quarter. Moors & Cabot Inc. now owns 1,639 shares of the insurance provider's stock worth $519,000 after acquiring an additional 40 shares in the last quarter. Mather Group LLC. raised its holdings in Humana by 21.0% during the fourth quarter. Mather Group LLC. now owns 236 shares of the insurance provider's stock worth $60,000 after acquiring an additional 41 shares in the last quarter. Finally, Capital Advisors Ltd. LLC raised its holdings in Humana by 26.1% during the fourth quarter. Capital Advisors Ltd. LLC now owns 208 shares of the insurance provider's stock worth $53,000 after acquiring an additional 43 shares in the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Insider Activity at Humana

In related news, insider Timothy S. Huval sold 3,703 shares of the firm's stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the transaction, the insider now directly owns 8,181 shares of the company's stock, valued at $2,096,463.06. This trade represents a 31.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.32% of the stock is currently owned by company insiders.

Humana Price Performance

Shares of HUM stock traded down $5.90 during trading hours on Friday, reaching $259.86. The company's stock had a trading volume of 1,552,919 shares, compared to its average volume of 1,673,380. The firm's 50 day simple moving average is $271.80 and its 200-day simple moving average is $284.13. The company has a market capitalization of $31.35 billion, a price-to-earnings ratio of 26.12, a PEG ratio of 2.05 and a beta of 0.57. Humana Inc. has a fifty-two week low of $213.31 and a fifty-two week high of $406.46. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68.

Humana (NYSE:HUM - Get Free Report) last issued its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, beating analysts' consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. Sell-side analysts forecast that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be issued a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a dividend yield of 1.36%. The ex-dividend date is Friday, March 28th. Humana's dividend payout ratio (DPR) is 35.58%.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Truist Financial upped their target price on Humana from $260.00 to $290.00 and gave the stock a "hold" rating in a report on Monday, January 6th. Piper Sandler upped their price objective on Humana from $270.00 to $288.00 and gave the company a "neutral" rating in a research note on Wednesday, January 15th. JPMorgan Chase & Co. dropped their price objective on Humana from $257.00 to $256.00 and set a "neutral" rating on the stock in a research note on Tuesday, February 18th. StockNews.com lowered Humana from a "buy" rating to a "hold" rating in a research note on Wednesday. Finally, Morgan Stanley dropped their price objective on Humana from $301.00 to $285.00 and set an "equal weight" rating on the stock in a research note on Wednesday, February 12th. Twenty investment analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $285.68.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.